A traditional Amazonian bark, sold mainly as a few patented, standardised extracts. Best-measured effect: fewer painful, tender joints in arthritis, relief appearing quickly. Single small studies also suggest steadier antibody levels after vaccination and better day-to-day functioning in advanced cancer. Safety reporting is reassuring but shallow. Overall a modest, narrow benefit rarely repeated, on a commercially entangled evidence base. (Full Review)
| Marker | Target | Why |
|---|---|---|
| hs-CRP | Below 0.5 mg/L | Tracks the inflammation the extract is meant to lower |
| Neutrophil count | 1.8–5.0 ×10⁹/L | The white cell measure that moved in the chemotherapy trial |
| Lymphocyte-to-neutrophil ratio | 0.4 or above | The immune shift reported in the vaccine study |
| Serum creatinine | 0.6–1.0 mg/dL in women, 0.8–1.2 mg/dL in men | Detects the kidney injury described in case reports |
| eGFR | Above 90 mL/min/1.73 m² | Confirms kidney filtering reserve before and during use |
| ALT and AST | Both below 20 U/L | Standard safety check for any concentrated botanical extract |
| Seated blood pressure | Below 120/80 mmHg | Some alkaloids relax blood vessels, and additive lowering is plausible |
| Trough level of any narrow-therapeutic-index CYP3A4 substrate | The prescribing laboratory's stated window for that drug | The best-documented harm on record |
Cadence: Baseline before the first dose; kidney and liver panels repeated at four weeks; full review at twelve weeks against the symptom score; every six months thereafter, with an extra panel after any change in co-medication. Trough drug levels two weeks after starting and two weeks after stopping.